Abstract
SCLC has a high response rate to first line chemotherapy but this is often short lived. Patients who relapse six months after first line chemotherapy can be retreated with platinum ± etoposide and patients that relapse early are treated with CAV (cyclophosphamide, doxorubicin and vincristine), Topotecan or best supportive care (BSC). There have been no clinical trials comparing oral Topotecan with iv CAV.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
